Seres Therapeutics, Inc. Restructuring Charges
Seres Therapeutics, Inc. (MCRB) reported Restructuring Charges of $914.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-05
- Seres Therapeutics, Inc. restructuring charges for the quarter ending 2026-06-30 was $0.00.
- Seres Therapeutics, Inc. restructuring charges for the quarter ending 2026-03-31 was $914.00K.
- Seres Therapeutics, Inc. restructuring charges for the quarter ending 2025-12-31 was $0.00.
- Seres Therapeutics, Inc. restructuring charges for the quarter ending 2025-09-30 was $1.03M.
- Seres Therapeutics, Inc. restructuring charges for fiscal 2025 was $1.03M.
- Seres Therapeutics, Inc. restructuring charges for fiscal 2023 was $5.61M.
- Seres Therapeutics, Inc. restructuring charges for fiscal 2021 was $0.00.
- Seres Therapeutics, Inc. restructuring charges for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $914.00K 10-Q · filed 2026-08-05 | $914.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $914.00K 10-Q · filed 2026-05-05 | $914.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.94M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.03M derived: sum of 2 quarters · filed 2026-03-12 | $1.03M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $1.03M 10-Q · filed 2025-11-05 | $1.03M 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $5.61M 10-K · filed 2026-03-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-28 | $0.00 10-Q · filed 2020-07-28 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $1.49M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $1.49M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 | $1.49M 10-Q · filed 2020-07-28 | ||
| 2019-03-31 | $1.49M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-02 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |